1. Home
  2. TSI vs PROF Comparison

TSI vs PROF Comparison

Compare TSI & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TCW Strategic Income Fund Inc.

TSI

TCW Strategic Income Fund Inc.

HOLD

Current Price

$4.51

Market Cap

221.5M

Sector

Finance

ML Signal

HOLD

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

N/A

Current Price

$6.91

Market Cap

243.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TSI
PROF
Founded
1987
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
221.5M
243.2M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
TSI
PROF
Price
$4.51
$6.91
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
114.4K
66.8K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
7.46%
N/A
EPS Growth
N/A
25.89
EPS
N/A
0.19
Revenue
N/A
$16,098,000.00
Revenue This Year
N/A
$92.40
Revenue Next Year
N/A
$64.10
P/E Ratio
N/A
$36.61
Revenue Growth
N/A
50.73
52 Week Low
$4.43
$3.92
52 Week High
$5.06
$8.95

Technical Indicators

Market Signals
Indicator
TSI
PROF
Relative Strength Index (RSI) 41.04 51.69
Support Level $4.43 $5.81
Resistance Level $4.63 $7.07
Average True Range (ATR) 0.03 0.41
MACD -0.00 -0.04
Stochastic Oscillator 0.00 26.72

Price Performance

Historical Comparison
TSI
PROF

About TSI TCW Strategic Income Fund Inc.

Tcw Strategic Income Fund Inc operates as a diversified closed-end management investment company. The investment objective of the company is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as banks, beverages, biotechnology, chemicals, commercial services, and others.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Share on Social Networks: